Ascenta Capital, a private equity and venture capital firm, led a $101m Series C round in Odyssey Therapeutics, a biotechnology company, with participation from OrbiMed, SR One, General Catalyst, Foresite Capital, Woodline Partners, HBM Healthcare Investments, Colt Ventures, BlackMars Capital, Creacion Ventures, Fidelity Management & Research Company, T. Rowe Price Associates, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, Racing Beach Ventures, The Healthcare Innovation Investment Fund, Leerink Partners, Ab Magnitude Ventures, KB Investment and The Global BioAccess Fund. “Odyssey has rapidly advanced a portfolio of immunology and oncology therapeutics with the goal of providing transformative medicines for large numbers of patients in need and several of these molecules have the potential to enter the clinic in the next 12 months. For us, success is defined as bringing safe and effective medicines to patients with serious diseases, with support from Ascenta and our other investors driving our pipeline into the future. We welcome Dr. Lorence Kim, co-founder and managing partner of Ascenta Capital, to our board to join us in achieving this mission,” Gary D. Glick, Odyssey Therapeutics Founder and CEO.